UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 532

Sortiert nach

High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

Journal of clinical oncology, 2001-05, Vol.19 (9), p.2370-2380

2001

Volltextzugriff (PDF)

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Annals of oncology, 2017-02, Vol.28 (2), p.368-376

2017

Volltextzugriff (PDF)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells

Oncogene, 2016-03, Vol.35 (10), p.1225-1235

2016

Volltextzugriff (PDF)

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2015-11, Vol.373 (19), p.1803-1813

2015

Volltextzugriff (PDF)

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

The New England journal of medicine, 2012-09, Vol.367 (13), p.1187-1197

2012

Volltextzugriff (PDF)

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study

Journal of clinical oncology, 1998-02, Vol.16 (2), p.664-669

1998

Volltextzugriff (PDF)

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production

Blood, 1997-10, Vol.90 (7), p.2541

1997

Volltextzugriff (PDF)

Pilot Trial of Interleukin-2 With Granulocyte Colony-Stimulating Factor for the Mobilization of Progenitor Cells in Advanced Breast Cancer Patients Undergoing High-Dose Chemotherapy: Expansion of Immune Effectors Within the Stem-Cell Graft and Post–Stem-Cell Infusion

Journal of clinical oncology, 2001-02, Vol.19 (3), p.634-644

2001

Volltextzugriff (PDF)

Sunlight and Reduced Risk of Cancer: Is The Real Story Vitamin D?

JNCI : Journal of the National Cancer Institute, 2005-02, Vol.97 (3), p.161-163

2005

Volltextzugriff (PDF)

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma

Journal of clinical oncology, 1994-08, Vol.12 (8), p.1553-1560

1994

Volltextzugriff (PDF)

Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration

Clinical cancer research, 1995-08, Vol.1 (8), p.805-812

1995

Volltextzugriff (PDF)

Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma

Journal of clinical oncology, 1994-01, Vol.12 (1), p.176-183

1994

Volltextzugriff (PDF)

A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients

Annals of oncology, 1994-05, Vol.5 (5), p.447-452

1994

Volltextzugriff (PDF)

Daily Subcutaneous Ultra-Low-Dose Interleukin 2 with Daily Low-Dose Interferon-α in Patients with Advanced Renal Cell Carcinoma

Clinical cancer research, 1999-09, Vol.5 (9), p.2374-2380

1999

Volltextzugriff (PDF)

Repetitive Weekly Cycles of Interleukin-2. II. Clinical and Immunologic Effects of Dose, Schedule, and Addition of Indomethacin

JNCI : Journal of the National Cancer Institute, 1988-11, Vol.80 (18), p.1451-1461

1988

Volltextzugriff (PDF)

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity

Clinical cancer research, 1997-01, Vol.3 (1), p.39-46

1997

Volltextzugriff (PDF)

Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma

Anticancer research, 2000-05, Vol.20 (3B), p.1965

2000

Volltextzugriff (PDF)

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer

Cancer research (Chicago, Ill.), 1988-05, Vol.48 (9), p.2561-2567

1988

Volltextzugriff (PDF)

Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity

JNCI : Journal of the National Cancer Institute, 1988-03, Vol.80 (1), p.60-63

1988

Volltextzugriff (PDF)

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025

European urology, 2017-09, Vol.72 (3), p.368-376

2017

Volltextzugriff (PDF)

Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects

Journal of clinical oncology, 1993-08, Vol.11 (8), p.1496-1505

1993

Volltextzugriff (PDF)

Food-dependent exercise-induced anaphylaxis

Journal of allergy and clinical immunology, 1983-01, Vol.71 (4), p.407-411

1983

Volltextzugriff (PDF)

Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen

The Prostate, 1997-02, Vol.30 (2), p.73-78

1997

Volltextzugriff (PDF)

Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone

Annals of oncology, 2016-10, Vol.27, p.vi379-vi379

2016

Volltextzugriff (PDF)

Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib

Journal of clinical oncology, 2005-11, Vol.23 (31), p.7889-7896

2005

Volltextzugriff (PDF)

1 – 25 von 532

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(489)
Mit Volltextzugriff
(439)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production

Pilot Trial of Interleukin-2 With Granulocyte Colony-Stimulating Factor for the Mobilization of Progenitor Cells in Advanced Breast Cancer Patients Undergoing High-Dose Chemotherapy: Expansion of Immune Effectors Within the Stem-Cell Graft and Post–Stem-Cell Infusion

Sunlight and Reduced Risk of Cancer: Is The Real Story Vitamin D?

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma

Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration

Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma

A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients

Daily Subcutaneous Ultra-Low-Dose Interleukin 2 with Daily Low-Dose Interferon-α in Patients with Advanced Renal Cell Carcinoma

Repetitive Weekly Cycles of Interleukin-2. II. Clinical and Immunologic Effects of Dose, Schedule, and Addition of Indomethacin

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity

Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer

Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025

Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects

Food-dependent exercise-induced anaphylaxis

Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen

Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone

Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib

Suchergebnisse filtern